Paulo Fontoura, MD, PhD
from Neurology Reviews
Dr. Fontoura examines the effect that ocrelizumab has on the composite end point of no evidence of disease progression in MS.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Neurology Reviews?
This episode is 4 minutes long.
When was this Neurology Reviews episode published?
This episode was published on September 28, 2018.
Can I download this Neurology Reviews episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.